MPI: The Future of Biomedical Molecular Imaging?
Peter Caravan, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, USA
MPI shows great optimism for molecular imaging: potentially low cost device, shelf-stable molecular probes, no ionizing radiation, direct detection of the probe, and relatively high sensitivity for detection. Drawing upon other modalities, this lecture will describe the requirements for successful MPI applications.
The ultimate utility of MPI is somewhat bounded by the need to utilize nanoparticle-based probes which are limited in their pharmacokinetic properties and biodistribution. Acknowledging and working within these constraints still leaves a broad field of impactful application. Here we will describe possible avenues for molecular probes that take advantage of this powerful emerging technology.
|1997||PhD in Chemistry, University of British Columbia|
|1998||Post-doctoral fellow, Chemistry, Université de Lausanne|
|04/07-02/08||Instructor, Radiology, Harvard Medical School|
|02/08-09/13||Assistant Professor, Radiology, Harvard Medical School|
|10/13 -||Associate Professor, Professor, Radiology, Harvard Medical School|
|2014 -||Co-Director, Institute for Innovation in Imaging: Establish, direct, and manage translational imaging institute|
The schedule of IWMPI 2019 is continuously updated.